Sutro Biopharma (NASDAQ: STRO) — Company Overview, News & Financial Data
Sutro Biopharma develops biopharmaceuticals using innovative technologies to treat cancer and autoimmune disorders.
Sutro Biopharma
Sutro Biopharma (NASDAQ:STRO) specializes in the development of biopharmaceuticals using its distinctive cell-free protein synthesis and site-specific conjugation platforms, aimed at improving the treatment of cancer and auto-immune disorders. The company's pipeline is robust, consisting of several oncology programs that are both wholly owned and in collaboration with key industry partners. Sutro's objectives are centered around advancing its clinical and preclinical programs to provide innovative therapies that can significantly improve patient outcomes. This includes leveraging their proprietary technology to streamline the discovery, development, and manufacturing processes, ensuring rapid and efficient delivery of their therapeutic candidates.
Snapshot
Operations
Products and/or services of Sutro Biopharma
- STRO-001, a CD74-targeting antibody-drug conjugate aimed at treating B-cell malignancies.
- STRO-002, an anti-folate receptor alpha antibody-drug conjugate for ovarian and endometrial cancers.
- Cytokine-based therapeutics focusing on next-generation cancer and autoimmune disease treatments.
- Bispecific antibodies designed to target cancer cells by engaging two different targets simultaneously.
- Collaboration with Merck to develop and commercialize novel immune-modulating therapies for cancer treatment.
Sutro Biopharma executive team
- Jane ChungCEO & Director
- Gregory K. ChowChief Financial Officer
- Hans-Peter GerberChief Scientific Officer
- James R. SwartzFounder
- Devendra LuharSenior Vice President of Technical Operations
- Kari E. LeetchSenior VP and Head of People & Culture
- Jonathan FawcettVP & Head of Clinical Development
- Lucas DonigianSenior Vice President of Business Development
- Regina ChengVice President & Controller